Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

Current Medical Research and Opinion

Volumn 21, Issue 9, 2005, Pages 1453-1460

  Cramer, Joyce A ^a   Amonkar, Mayur M ^b   Hebborn, Ansgar ^c   Altman, Roy ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bisphosphonates; Compliance; Persistence; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG USE; FEMALE; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION;

AGE FACTORS; AGED; ALENDRONATE; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; MANAGED CARE PROGRAMS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; SELF ADMINISTRATION; UNITED STATES;

EID: 25444477545     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X61875     Document Type: Conference Paper

References (37)

1. Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107-10
2. Melton LJ III. How many women have osteoporosis now? J Bone Miner Res 1995;10:175-7
3. Kanis JA, Geusens P, Christiansen C. Guidelines for clinical trials in osteoporosis: a position paper of the European Foundation for Osteoporosis and Bone Disease. Osteoporosis Int 1991;1:182-8
4. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass in our nation. National Osteoporosis Foundation, 2002
5. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646-56
6. Johnell O, Kanis JA. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 2004;15:897-902
7. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24-35
8. Melton LJ III. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003;18:1139-41
9. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2004;9:544-64
10. Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 2003;72:297
11. Finigan J, Bainbridge PR, Eastell R. Adherence to osteoporosis therapies. Osteoporos Int 2001;12:S48-9 [abstract P110)]
12. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-8
13. Sebaldt RJ, Shane LG, Pham B, et al. Longer term effectiveness outcomes of noncompliance and nonpersistence with daily regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int 2004;15(Suppl 1): S107 [abstract P391SA]
14. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8
15. Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 2001;15: S529 [abstract M406]
16. Negri AL. Short-term compliance with alendronate 70 mg in patients with osteoporosis: The ECMO Trial. Bone 2003;23(Suppl):P487 [abstract]
17. Bandeira F, Kayath M, Marques-Neto J, et al. Patients' clinical features and compliance associated with raloxifine or alendronate after a six-month observational Brazilian study. J Bone Miner Res 2003;18(Suppl 2):S379 [abstract M352]
18. Ettinger B, Pressman AR, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions and discontinuation. J Managed Care Pharm 1998;4:488-92
19. Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003;14:808-13
20. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomised, open-label, crossover study. Clin Ther 2002;24:1871-86
21. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3:417-26
22. Breekveldt-Postma NS, Herings R. Persistence with antihypertensives related to formulation: the case of nifedipine. Ann Pharmacother 2005;39:237-42
23. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004;113:245-51
24. Schiff I, Rebar RW, Cramer JA, et al. Achieving long-term continuance of menopausal ERT/HRT: consensus opinion of the North American Menopause Society. Menopause 1998;5:69-76
25. Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 1998;12:7-15
26. Prestwood KM. Osteoporosis: up-to-date strategies for prevention and treatment. Geriatrics 1997;52:92-4,97-8
27. Gallagher JC. Pathophysiology of osteoporosis. Semin Nephrol 1992;12:109-15
28. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone Survey. JAMA 2002;287:337-44
29. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7
30. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201
31. Cramer JA. Consequences of intermittent treatment for hypertension: The case for medication compliance and persistence. Am J Managed Care 1998;4:1563-8
32. Venturini F, Nichol MB, Sung JC, et al. Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother 1999;33:281-8
33. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
34. Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988;26:814-23
35. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:1074-90
36. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: Methods, validity, and application. J Clin Epidemiol 1997;50:105-16
37. Cramer JA. Overview of methods to measure and enhance patient compliance. In: Cramer JA, Spilker B, editors. Patient Compliance in Medical Practice and Clinical Trials. New York, NY: Raven Press, 1991, pp.3-10